常染色体显性多囊肾病的血管功能障碍、氧化应激与炎症
本研究在早期常染色体显性多囊肾病(ADPKD)患者(eGFR≥60 ml/min per 1.73 m2)及健康对照中评估动脉僵硬度和血管内皮功能,发现ADPKD患者颈-股脉搏波速度更高,抗坏血酸输注可改善血流介导的血管扩张,提示血管氧化应激和炎症参与ADPKD血管功能障碍。
要点
- 早期ADPKD患者已存在动脉僵硬度增加。
- 抗坏血酸可改善ADPKD患者的内皮依赖性血管扩张。
- ADPKD患者内皮细胞NF-κB表达增加,提示炎症激活。
核心结论
- 结果支持血管氧化应激和炎症随ADPKD发生发展的假说。
研究设计与样本
- 研究纳入61例早期ADPKD患者(34±9岁)和19例健康对照(30±5岁)。
- 评估颈-股脉搏波速度(动脉僵硬度)和肱动脉血流介导的血管扩张(内皮功能)。
- 在输注抗坏血酸抑制血管氧化应激后再次评估血流介导的血管扩张,并与生理盐水比较。
- 收集外周静脉内皮细胞测量蛋白表达,并用ELISA或液相色谱-串联质谱评估循环标志物。
主要发现
- ADPKD患者颈-股脉搏波速度高于健康对照(650±131 vs 562±81 cm/s;P=0.007)。
- ADPKD患者肱动脉血流介导的血管扩张为8.2%±5.8%,对照为10.8%±4.7%(P=0.08)。
- ADPKD患者输注抗坏血酸后血流介导的血管扩张从7.7%±4.5%增至9.4%±5.2%,差值为1.72(95%CI 0.80至2.63);对照则从10.8%±4.7%变为10.6%±5.4%,差值为-0.20(95%CI -1.24至0.84;交互P=0.02)。
- ADPKD患者内皮细胞NF-κB蛋白表达高于对照(0.48±0.12 vs 0.41±0.10;P=0.03)。
- 循环氧化应激标志物和生物活性脂质介质在ADPKD诊断间无显著差异。
临床怎么用
- 在早期ADPKD且血压控制良好的患者中,应关注血管功能障碍的评估。
- 抗坏血酸改善内皮功能提示氧化应激是可干预的靶点,但需进一步研究确认临床获益。
局限性
- 样本量较小,仅纳入早期ADPKD且血压控制良好的患者。
- 未直接证实循环氧化应激标志物差异,机制证据部分来源于内皮细胞蛋白表达。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Both increased arterial stiffness and vascular endothelial dysfunction are evident in patients with autosomal dominant polycystic kidney disease, even early in the course of the disease when kidney function in preserved. Vascular dysfunction in autosomal dominant polycystic kidney disease is thought to be related to vascular oxidative stress and inflammation, but direct evidence is lacking. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We assessed carotid-femoral pulse-wave velocity (arterial stiffness) and brachial artery flow-mediated dilation (vascular endothelial function) in participants with early-stage autosomal dominant polycystic kidney disease (eGFR≥60 ml/min per 1.73 m2) and a history of controlled hypertension and in healthy controls. Brachial artery flow-mediated dilation was also assessed after infusion of ascorbic acid to inhibit vascular oxidative stress compared with saline. Vascular endothelial cells were collected from a peripheral vein to measure expression of proteins, and circulating markers were also assessed by ELISA or liquid chromatography-tandem mass spectrometry. RESULTS: In total, 61 participants with autosomal dominant polycystic kidney disease (34±9 years old [mean±SD]) and 19 healthy controls (30±5 years old) were studied. Carotid-femoral pulse-wave velocity was higher in participants with autosomal dominant polycystic kidney disease compared with healthy controls (650±131 versus 562±81 cm/s; P=0.007). Brachial artery flow-mediated dilation was 8.2%±5.8% in participants with autosomal dominant polycystic kidney disease and 10.8%±4.7% in controls (P=0.08). Among participants with autosomal dominant polycystic kidney disease, flow-mediated dilation increased from 7.7%±4.5% to 9.4%±5.2% with ascorbic acid, a difference of 1.72 (95% confidence interval, 0.80 to 2.63), whereas in control participants, flow-mediated dilation decreased nonsignificantly from 10.8%±4.7% to 10.6%±5.4%, a difference of -0.20 (95% confidence interval, -1.24 to 0.84; P interaction =0.02). Endothelial cell protein expression of NF-κB was greater in participants with autosomal dominant polycystic kidney disease (0.48±0.12 versus 0.41±0.10 [intensity versus human umbilical vein endothelial cell control]; P=0.03). However, circulating oxidative stress markers and bioactive lipid mediators did not significantly differ according to the autosomal dominant polycystic kidney disease diagnosis. CONCLUSIONS: These results provide support for the hypothesis that vascular oxidative stress and inflammation develop with autosomal dominant polycystic kidney disease. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_09_18_CJASNPodcast_18_10_.mp3.
引用
- Nowak KL, Wang W, Farmer-Bailey H, et al. Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2018. PMID: 30228110. doi:10.2215/CJN.05850518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。